Figure 1

Insulin, metformin, BLX-1002, rosuvastatin, pioglitazone, candesartan and glimepiride increase HCAEC viability. Cells were incubated for 48 h in medium supplemented with 0.5% FBS in the presence or absence of insulin lispro (100 pM and 1 nM), metformin (500 μM), BLX-1002 (1 μM), rosuvastatin (10 nM), pioglitazone (2.5 μM), candesartan (100 nM) and glimepiride (1 μM). Viability was assessed with Trypan blue exclusion. * denotes P < 0.05, ** denotes P < 0.01, *** denotes P < 0.001 for chance differences compared to controls by Student's t-test.